IL-6 transgenic mouse model for extraosseous plasmacytoma

Plasma cell neoplasms in humans comprise plasma cell myeloma, otherwise known as multiple myeloma, Ig deposition and heavy chain diseases, and plasmacytoma (PCT). A subset of PCT, designated extramedullary PCT, is distinguished from multiple myeloma and solitary PCT of bone by its distribution among various tissue sites but not the bone marrow. Extramedullary (extraosseus) PCT are rare spontaneous neoplasms of mice but are readily induced in a susceptible strain, BALB/c, by treatment with pristane. The tumors develop in peritoneal granulomas and are characterized by Myc-activating T(12;15) chromosomal translocations and, most frequently, by secretion of IgA. A uniting feature of human and mouse plasma cell neoplasms is the critical role played by IL-6, a B cell growth, differentiation, and survival factor. To directly test the contribution of IL-6 to PCT development, we generated BALB/c mice carrying a widely expressed IL-6 transgene. All mice exhibited lymphoproliferation and plasmacytosis. By 18 months of age, over half developed readily transplantable PCT in lymph nodes, Peyer's patches, and sometimes spleen. These neoplasms also had T(12;15) translocations, but remarkably, none expressed IgA. Unexpectedly, ≈30% of the mice developed follicular and diffuse large cell B cell lymphomas that often coexisted with PCT. These findings provide a unique model of extramedullary PCT for studies on pathogenesis and treatment and suggest a previously unappreciated role for IL-6 in the genesis of germinal center-derived lymphomas.

[1]  T. Honjo,et al.  In situ class switching and differentiation to IgA-producing cells in the gut lamina propria , 2001, Nature.

[2]  N. Copeland,et al.  Combined histologic and molecular features reveal previously unappreciated subsets of lymphoma in AKXD recombinant inbred mice. , 2001, Leukemia research.

[3]  R. DePinho,et al.  Efficiency Alleles of the Pctr1 Modifier Locus for Plasmacytoma Susceptibility , 2001, Molecular and Cellular Biology.

[4]  M. Amiot,et al.  The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. , 2000, European cytokine network.

[5]  M. Frazier-Jessen,et al.  Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. , 2000, Blood.

[6]  A. Kovalchuk,et al.  Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain μ locus and c-myc , 2000, Leukemia.

[7]  T. Hirano,et al.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.

[8]  A. Kovalchuk,et al.  Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations , 2000, Leukemia.

[9]  H. Morse,et al.  Accelerated Appearance of Multiple B Cell Lymphoma Types in NFS/N Mice Congenic for Ecotropic Murine Leukemia Viruses , 2000, Laboratory Investigation.

[10]  P. L. Bergsagel,et al.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Naka,et al.  Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. , 1999, Trends in biochemical sciences.

[12]  M. Potter,et al.  BALB/c.CBA/N mice carrying the defective Btk(xid) gene are resistant to pristane-induced plasmacytomagenesis. , 1999, International immunology.

[13]  T. Hirano,et al.  Stat3 Is Required for the Gp130-mediated Full Activation of the C-myc Gene , 1999 .

[14]  Y. Uchiyama,et al.  Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Naka,et al.  Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Kovalchuk,et al.  Deletional remodeling of c-myc-deregulating chromosomal translocations , 1997, Oncogene.

[17]  P. Musiani,et al.  Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. , 1997, The American journal of pathology.

[18]  W. Leonard,et al.  Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway. , 1996, Immunity.

[19]  E. Shacter,et al.  Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Musiani,et al.  IL‐6 Expression in Neurons of Transgenic Mice Causes Reactive Astrocytosis and Increase in Ramified Microglial Cells but no Neuronal Damage , 1995, The European journal of neuroscience.

[21]  M. Potter,et al.  Differences between Burkitt's lymphomas and mouse plasmacytomas in the immunoglobulin heavy chain/c-myc recombinations that occur in their chromosomal translocations. , 1995, Cancer research.

[22]  S. Rudikoff,et al.  Interleukin 6 is essential for in vivo development of B lineage neoplasms , 1995, The Journal of experimental medicine.

[23]  A. Rolink,et al.  An interleukin‐6 transgene expressed in B lymphocyte lineage cells overcomes the T cell‐dependent establishment of normal levels of switched immunoglobulin isotypes , 1995, European journal of immunology.

[24]  M. Potter,et al.  Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Stripp,et al.  Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity. , 1994, The Journal of clinical investigation.

[26]  G. Ciliberto,et al.  Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. , 1994, Blood.

[27]  M. Potter,et al.  Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice. , 1994, Cancer research.

[28]  L. Mucke,et al.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Shaughnessy,et al.  Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Rudikoff,et al.  In vitro culture of primary plasmacytomas requires stromal cell feeder layers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Potter,et al.  Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. , 1992, Carcinogenesis.

[32]  U. Rüther,et al.  Long-term consequences of interleukin-6 overexpression in transgenic mice. , 1992, DNA and cell biology.

[33]  D. Longo,et al.  MYC rearrangements in histologically progressed follicular lymphomas. , 1992, Blood.

[34]  E. Fuchs,et al.  Interleukin 6: insights to its function in skin by overexpression in transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Largaespada,et al.  A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. , 1992, Oncogene.

[36]  J. Miyazaki,et al.  Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Renauld,et al.  Materials and Methods Briefdefinitive Report , 2022 .

[38]  T. Hirano,et al.  Interleukin 6 induces secretion of IgG1 by coordinated transcriptional activation and differential mRNA accumulation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Miyazaki,et al.  IgG1 plasmacytosis in interleukin 6 transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. de Jong,et al.  Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. , 1988, The New England journal of medicine.

[41]  R. Nordan,et al.  A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. , 1986, Science.

[42]  S. Cory.  Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. , 1986, Advances in cancer research.

[43]  J. Pumphrey,et al.  Genetics of Susceptibility to Plasmacytoma Induction. I. BALB/cAnN (C), C57BL/6N (B6), C57BL/Ka (BK), (C × B6)F1, (C × BK) F1, and C × B Recombinant-Inbred Strains , 1975 .